covid-19. covid-19
Conditions
Interventions
Intervention 1: Intervention group 1: standard local treatment + infleximab (5mg / kg / dose only single dose as intravenous infusion given to the patient within 2 hours). Intervention 2: Intervention
Sponsors
World Health Organization
Deputy of Research and Technology, Ministry of Health and Medical Education
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Hospitalized patients with laboratory-confirmed COVID-19 Adults (age =18 years( Not expected to be transferred within 72 hours
Exclusion criteria
Exclusion criteria: In the view of their doctors, no contraindication to use relevant drugs No evidence of pregnancy or hepatic disease in imatinib group No evidence of heart failure, TB or liver disease in Infliximab group
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In-hospital death from any causes. Timepoint: At the end of study. Method of measurement: Physician report. | — |
Secondary
| Measure | Time frame |
|---|---|
| In-hospital mortality subdivided by initial respiratory support. Timepoint: At the end of study. Method of measurement: Physician report.;Initiation of ventilation (time to first ventilation) in lower-risk patients. Timepoint: During study. Method of measurement: Physician report.;Duration of hospital stay in lower-risk patients and in higher-risk patients. Timepoint: At the end of study. Method of measurement: Physician report.;SAEs (serious adverse events) or SUSARs (suspected unexpected serious adverse reaction) possibly related to treatment. Timepoint: During study. Method of measurement: Physician report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Zali
Shahid Beheshti University of Medical Sciences
Outcome results
None listed